130
Participants
Start Date
December 16, 2024
Primary Completion Date
September 30, 2026
Study Completion Date
December 31, 2026
Inclisiran
Inclisiran sodium 300 mg/1.5 ml (equivalent to 284 mg inclisiran liquid) in prefilled syringe (PFS).
Temple University, Philadelphia
JHU - Suburban Hospital, Bethesda
Johns Hopkins, Columbia
Wake Forest University, Winston-Salem
University of North Carolina, Chapel Hill
Duke University Medical Center, Durham
Medical Univ. of South Carolina, Charleston
Wellstar Paulding, Hiram
Emory University, Atlanta
Univ. of Alabama - Birmingham, Birmingham
University of Iowa, Iowa City
Medical College of Wisconsin, Milwaukee
Essentia Health, Duluth
Rush University, Chicago
Washington University, St Louis
University of Missouri, Columbia
University of Nebraska, Omaha
Baylor Scott & White - Waco, Waco
Houston Methodist, Houston
University of Utah, Salt Lake City
Univ. of California - Irvine, Orange
San Francisco General Hospital, San Francisco
Heart House of NJ, Haddon Heights
Lead Sponsor
Collaborators (1)
Novartis Pharmaceuticals
INDUSTRY
Duke University
OTHER